Multi-specific binding proteins for cancer treatment
The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
1. A protein comprising a first antigen binding unit specifically binding to DLL3 and a second antigen binding unit specifically binding to CD3, wherein said first antigen binding unit specifically binding to DLL3 is
an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3).
2. The protein of claim 1 , wherein said first antigen binding unit specifically binding to DLL3 comprises a first light chain variable domain and a first heavy chain variable domain and is
an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42.
3. The protein of claim 1 , wherein said second antigen binding unit specifically binding to CD3 is
an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3).
4. The protein of claim 1 , wherein said second antigen binding unit specifically binding to CD3 comprises a second light chain variable domain and a second heavy chain variable domain:
wherein said light chain variable domain comprises the amino acid sequence of SEQ ID NO:67 and said heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:68.
5. The protein of claim 1 , wherein
i) said first antigen binding unit specifically binding to DLL3 comprises from its N- to C-terminus a first light chain variable domain, a first light chain constant domain, a first peptide linker, a first heavy chain variable domain and a first heavy chain constant CH1 domain; and
ii) said second antigen binding unit specifically binding to CD3 comprises from its N- to C-terminus a second light chain variable domain, a second light chain constant domain, a second peptide linker, a second heavy chain variable domain and a second heavy chain constant CH1 domain.
6. The protein of claim 5 , wherein said first and/or second peptide linker comprises 26 to 42 amino acids, 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids.
7. The protein of claim 5 , wherein said first linker and/or second linker is a Glycine-Serine linker comprising the amino acid sequence of SEQ ID NO:89, and wherein said first and second peptide linker comprise the same sequence.
8. The protein of claim 5 , further comprising a first and a second Fc domain, said first Fc domain covalently linked to said first antigen binding unit, and a said second Fc domain covalently linked to said second antigen binding unit.
9. The protein of claim 8 , wherein
i) said first human IgG1 Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said second human IgG1 Fc domain comprises a threonine (T) at position 407 [Y407T], or
ii) said first human IgG1 Fc domain comprises a tryptophan (W) at position 366 [T366W], and said second human IgG1 Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or
iii) said second human IgG1 Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said first human IgG1 Fc domain comprises a threonine (T) at position 407 [Y407T], or
iv) said second human IgG1 Fc domain comprises a tryptophan (W) at position 366 [T366W], and said first human IgG1 Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V],
wherein said first or said second human IgG1 Fc domain optionally further comprises an arginine at position 435 [H435R] and a phenylalanine at position 436 [Y436F],
wherein numbering of the amino acids of the human IgG1 Fc domain are according to the EU numbering system.
10. The protein of claim 9 , wherein said first and/or said second human IgG1 Fc domain further comprises an alanine at position 234[L234A] and at position 235 [L235A] wherein numbering of the amino acids of the IgG1 Fc domain are according to the EU numbering system.
11. The protein of claim 5 , wherein the first light chain constant domain and the second light chain constant domain comprise a human kappa or lambda domain.
12. A method of manufacturing a protein of claim 1 , comprising
i) cultivating a host cell transfected with an expression vector comprising a nucleic acid molecule encoding a first polypeptide chain for the first antigen binding unit specifically binding to DLL3, and an expression vector comprising a nucleic acid molecule encoding a second polypeptide chain for the second antigen binding unit specifically binding to CD3 under conditions allowing expression of the protein of claim 1 ; and
ii) recovering the protein; and optionally
iii) further purifying and/or modifying and/or formulating the protein.
13. A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
14. A protein comprising a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75, and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79.
15. An isolated nucleic acid molecule encoding the first and/or the second polypeptide chain of claim 14 .
16. An expression vector comprising the nucleic acid molecule of claim 15 .
17. A host cell transfected with the expression vector of claim 16 .